{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:59:01Z","timestamp":1793843941164,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recently, the clinical proof of concept for the first ultra-long oral insulin was reported, showing efficacy and safety similar to subcutaneously administered insulin glargine. Here, we report the molecular engineering as well as biological and pharmacological properties of these insulin analogues. Molecules were designed to have ultra-long pharmacokinetic profile to minimize variability in plasma exposure. Elimination plasma half-life of ~20\u2009h in dogs and ~70\u2009h in man is achieved by a strong albumin binding, and by lowering the insulin receptor affinity 500-fold to slow down receptor mediated clearance. These insulin analogues still stimulate efficient glucose disposal in rats, pigs and dogs during constant intravenous infusion and euglycemic clamp conditions. The albumin binding facilitates initial high plasma exposure with a concomitant delay in distribution to peripheral tissues. This slow appearance in the periphery mediates an early transient hepato-centric insulin action and blunts hypoglycaemia in dogs in response to overdosing.<\/jats:p>","DOI":"10.1038\/s41467-020-17487-9","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T10:03:22Z","timestamp":1595844202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Molecular engineering of safe and efficacious oral basal insulin"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-7900","authenticated-orcid":false,"given":"Frantisek","family":"Hub\u00e1lek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne H. F.","family":"Refsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-9397","authenticated-orcid":false,"given":"Sanne","family":"Gram-Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-7309","authenticated-orcid":false,"given":"Peter","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-3648","authenticated-orcid":false,"given":"Erica","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4504-8281","authenticated-orcid":false,"given":"Martin","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Lehn","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-3600","authenticated-orcid":false,"given":"Carsten Enggaard","family":"Stidsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Hove","family":"Claussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-3067","authenticated-orcid":false,"given":"Erik Max","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Pridal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Ribel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kildegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Porsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9330-5169","authenticated-orcid":false,"given":"Eva","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Bjerre","family":"Steensgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hovgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Glendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Falck","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja Kirkegaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Kresten","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend","family":"Ludvigsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Rugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Courtney","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-2560","authenticated-orcid":false,"given":"Alan D.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-9286","authenticated-orcid":false,"given":"Thomas","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"17487_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1136\/bmj.2.3286.1204","volume":"1923","author":"GA Harrison","year":"1923","unstructured":"Harrison, G. A. Insulin in alcoholic solution by the mouth. Br. Med. J. 1923, 1204\u20131205 (1923).","journal-title":"Br. Med. J."},{"key":"17487_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4155\/TDE.15.47","volume":"6","author":"M Lopes","year":"2015","unstructured":"Lopes, M., Sim\u00f5es, S., Veiga, F., Sei\u00e7a, R. & Ribeiro, A. Why most oral insulin formulations do not reach clinical trials. Ther. Deliv. 6, 973\u2013987 (2015).","journal-title":"Ther. Deliv."},{"key":"17487_CR3","unstructured":"Berger, M. in Frontiers in Insulin Pharmacology (eds Berger, M. & Gries, F.) 144\u2013148 (Plenum, Stuttgart, 1993)."},{"key":"17487_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1463-1326.2009.01150.x","volume":"12","author":"H Iyer","year":"2010","unstructured":"Iyer, H., Khedkar, A. & Verma, M. Oral insulin\u2014a review of current status. Diabetes Obes. Metab. 12, 179\u2013185 (2010).","journal-title":"Diabetes Obes. Metab."},{"key":"17487_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/1932296814529988","volume":"8","author":"E Zijlstra","year":"2014","unstructured":"Zijlstra, E., Heinemann, L. & Plum-M\u00f6rschel, L. Oral insulin reloaded: a structured approach. J. Diabetes Sci. Technol. 8, 458\u2013465 (2014).","journal-title":"J. Diabetes Sci. Technol."},{"key":"17487_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrd.2015.36","volume":"15","author":"AN Zaykov","year":"2016","unstructured":"Zaykov, A. N., Mayer, J. P. & DiMarchi, R. D. Pursuit of a perfect insulin. Nat. Rev. Drug Discov. 15, 425\u2013439 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"17487_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijpharm.2006.07.026","volume":"327","author":"N Zhang","year":"2006","unstructured":"Zhang, N. et al. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 327, 153\u2013159 (2006).","journal-title":"Int. J. Pharm."},{"key":"17487_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/dom.13498","volume":"21","author":"JM Gregory","year":"2019","unstructured":"Gregory, J. M. et al. Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. Diabetes Obes. Metab. 21, 160\u2013169 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"17487_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","volume":"7","author":"IB Halberg","year":"2019","unstructured":"Halberg, I. B. et al. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol. 7, 179\u2013188 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"17487_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s40262-019-00772-2","volume":"58","author":"IB Halberg","year":"2019","unstructured":"Halberg, I. B. et al. The effect of food intake on the pharmacokinetics of oral basal insulin: a randomised crossover trial in healthy male subjects. Clin. Pharmacokinet. 58, 1497\u20131504 (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"17487_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1517\/17425247.3.5.685","volume":"3","author":"TW Leonard","year":"2006","unstructured":"Leonard, T. W., Lynch, J., McKenna, M. J. & Brayden, D. J. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET\u2122. Expert Opin. Drug Deliv. 3, 685\u2013692 (2006).","journal-title":"Expert Opin. Drug Deliv."},{"key":"17487_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1023\/A:1015893832222","volume":"8","author":"RJ Schilling","year":"1991","unstructured":"Schilling, R. J. & Mitra, A. K. Degradation of insulin by trypsin and alpha-chymotrypsin. Pharm. Res. 8, 721\u2013727 (1991).","journal-title":"Pharm. Res."},{"key":"17487_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/bdd.2510160502","volume":"16","author":"TT Kararli","year":"1995","unstructured":"Kararli, T. T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory-animals. Biopharm. Drug Dispos. 16, 351\u2013380 (1995).","journal-title":"Biopharm. Drug Dispos."},{"key":"17487_CR14","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.amjmed.2014.07.005","volume":"127","author":"JM Tibaldi","year":"2014","unstructured":"Tibaldi, J. M. Evolution of insulin: from human to analog. Am. J. Med. 127, S25\u2013S38 (2014).","journal-title":"Am. J. Med."},{"key":"17487_CR15","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.2337\/db14-0266","volume":"63","author":"DS Edgerton","year":"2014","unstructured":"Edgerton, D. S. et al. Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog. Diabetes 63, 3946\u20133954 (2014).","journal-title":"Diabetes"},{"key":"17487_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13300-016-0214-7","volume":"8","author":"A Mu\u00f1oz-Garach","year":"2017","unstructured":"Mu\u00f1oz-Garach, A., Molina-Vega, M. & Tinahones, F. J. How can a good idea fail? Basal insulin Peglispro [LY2605541] for the treatment of type 2 diabetes. Diabetes Ther. 8, 9\u201322 (2017).","journal-title":"Diabetes Ther."},{"key":"17487_CR17","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2337\/db14-1364","volume":"64","author":"DP Begg","year":"2015","unstructured":"Begg, D. P. et al. Insulin detemir is transported from blood to cerebrospinal fluid and has prolonged central anorectic action relative to NPH insulin. Diabetes 64, 2457\u20132466 (2015).","journal-title":"Diabetes"},{"key":"17487_CR18","doi-asserted-by":"publisher","unstructured":"Abramson, A. et al. An ingestible self-orienting system for oral delivery of macromolecules. Science https:\/\/doi.org\/10.1126\/science.aau2277 (2019).","DOI":"10.1126\/science.aau2277"},{"key":"17487_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002530000402","volume":"54","author":"T Kjeldsen","year":"2000","unstructured":"Kjeldsen, T. Yeast secretory expression of insulin precursors. Appl. Microbiol. Biotechnol. 54, 277\u2013286 (2000).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"17487_CR20","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (glp-1) analogue semaglutide. J. Med. Chem. 58, 7370\u20137380 (2015).","journal-title":"J. Med. Chem."},{"key":"17487_CR21","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","volume":"29","author":"I Jonassen","year":"2012","unstructured":"Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104\u20132114 (2012).","journal-title":"Pharm. Res."},{"key":"17487_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejpb.2013.12.017","volume":"86","author":"SH Welling","year":"2014","unstructured":"Welling, S. H. et al. The role of citric acid in oral peptide and protein formulations: Relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm. 86, 544\u2013551 (2014).","journal-title":"J. Pharm. Biopharm."},{"key":"17487_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1107\/S0021889809042022","volume":"42","author":"F Gorrec","year":"2009","unstructured":"Gorrec, F. The MORPHEUS protein crystallization screen. J. Appl. Crystallogr. 42, 1035\u20131042 (2009).","journal-title":"J. Appl. Crystallogr."},{"key":"17487_CR24","doi-asserted-by":"crossref","unstructured":"Otwinowski, Z. & Minor, W. in Methods in Enzymology (ed, Charles W. Carter, Jr.) 276, 307\u2013326 (Academic Press, New York, 1997).","DOI":"10.1016\/S0076-6879(97)76066-X"},{"key":"17487_CR25","first-page":"125","volume":"D66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Cryst. D66, 125\u2013132 (2010).","journal-title":"Acta Cryst."},{"key":"17487_CR26","first-page":"213","volume":"D66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Cryst. D66, 213\u2013221 (2010).","journal-title":"Acta Cryst."},{"key":"17487_CR27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"17487_CR28","first-page":"486","volume":"D66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Cryst. D66, 486\u2013501 (2010).","journal-title":"Acta Cryst."},{"key":"17487_CR29","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2337\/db17-0979","volume":"67","author":"MC Moore","year":"2018","unstructured":"Moore, M. C. et al. Morning hyperinsulinemia primes the liver for glucose uptake and glycogen storage later in the day. Diabetes 67, 1237\u20131245 (2018).","journal-title":"Diabetes"},{"key":"17487_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2337\/diab.39.9.1033","volume":"39","author":"U Ribel","year":"1990","unstructured":"Ribel, U., Hougaard, P., Drejer, K. & Sorensen, A. R. Equivalent in vivo biological-activity of insulin analogs and human insulin despite different in vitro potencies. Diabetes 39, 1033\u20131039 (1990).","journal-title":"Diabetes"},{"key":"17487_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1463-1326.2010.01206.x","volume":"12","author":"AR Sorensen","year":"2010","unstructured":"Sorensen, A. R. et al. Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes Obes. Metab. 12, 665\u2013673 (2010).","journal-title":"Diabetes Obes. Metab."},{"key":"17487_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2983630","volume":"7","author":"EC Fieller","year":"1940","unstructured":"Fieller, E. C. The biological standardization of insulin. J. R. Stat. Soc. 7, 1\u201364 (1940).","journal-title":"J. R. Stat. Soc."},{"key":"17487_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/1087057106297566","volume":"12","author":"F Poulsen","year":"2007","unstructured":"Poulsen, F. & Jensen, K. B. A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J. Biomol. Screen. 12, 240\u2013247 (2007).","journal-title":"J. Biomol. Screen."},{"key":"17487_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jpba.2009.08.008","volume":"51","author":"SB Petersen","year":"2010","unstructured":"Petersen, S. B. et al. Comparison of a luminescent oxygen channeling immunoassay and an elisa for detecting insulin aspart in human serum. J. Pharm. Biomed. Anal. 51, 217\u2013224 (2010).","journal-title":"J. Pharm. Biomed. Anal."}],"updated-by":[{"DOI":"10.1038\/s41467-020-18106-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17487-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17487-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17487-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T21:07:16Z","timestamp":1723324036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17487-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["17487"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-17487-9","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-020-18106-3","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-020-18106-3","URL":"https:\/\/doi.org\/10.1038\/s41467-020-18106-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors except M.C.M. and A.D.C. are present or past employees of Novo Nordisk and hold equity in the company. M.C.M. and A.D.C. received financial support from Novo Nordisk. Insulin analogues and formulations described in this article are covered by Novo Nordisk\u2019s patents and patent applications. A.D.C. reports grants, personal fees, and other from Metavention, Zafgen, and Abvance; grants and\/or personal fees from Thetis Pharmaceuticals, Boston Scientific, Novo Nordisk, vTv Therapeutics, Merck, Eli Lilly, and Galvani Bioelectronics; personal fees from California Institute for Biomedical Research (Calibr) and MedImmune; personal fees and other from Fractyl, Biocon and Sensulin Labs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3746"}}